High Utilization Seen as GMP Issue Behind Cancer Drug Shortages

A lack of manufacturing capacity blamed for sterile injectable oncology drug shortages can be viewed as a GMP compliance issue, FDA official says, pointing to Section 211 process validation requirements. HHS analysis links the shortages to excessive utilization rates at generics firms.